TY - JOUR
T1 - Figueroa-García J, Granados-García V, Roldán-Valadez E, Rojano-Mejía D, Cruz-Toledo JE, Palomo-Piñón S. Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units. Salud Publica Mex. 2022;64:188-195.
AU - Figueroa-García, Juan
AU - Granados-García, Víctor
AU - Roldán-Valadez, Ernesto
AU - Rojano-Mejía, David
AU - Cruz-Toledo, Jairo Enoc
AU - Palomo-Piñón, Silvia
N1 - Publisher Copyright:
© 2022. All Rights Reserved.
PY - 2022
Y1 - 2022
N2 - Objective. To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. Materials and methods. A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, pharmacy records and unitary prices updated to 2019. Results. From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 10 dollars (CI95% 8.3,12) in the group of > 65 years. Conclusion. Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.
AB - Objective. To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. Materials and methods. A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, pharmacy records and unitary prices updated to 2019. Results. From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 10 dollars (CI95% 8.3,12) in the group of > 65 years. Conclusion. Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.
KW - Hipertensión
KW - Hypertension
KW - asignación de costo
KW - cost allocation
KW - drug therapy
KW - tratamiento farmacológico
UR - http://www.scopus.com/inward/record.url?scp=85128568876&partnerID=8YFLogxK
U2 - 10.21149/12972
DO - 10.21149/12972
M3 - Artículo
C2 - 35438925
AN - SCOPUS:85128568876
SN - 0036-3634
VL - 64
SP - 188
EP - 195
JO - Salud Publica de Mexico
JF - Salud Publica de Mexico
IS - 2
ER -